BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9085130)

  • 1. Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13?
    Reinsberg J; Krebs D
    Hybridoma; 1997 Feb; 16(1):59-63. PubMed ID: 9085130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
    Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
    Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immunization with an anti-CA 125 (MAb OC125) monoclonal antibody by activation of the idiotypic network.
    Schultes BC; Reinsberg J; Schlebusch H; Oehr P; Biersack HJ; Krebs D; Wagner U
    Eur J Clin Chem Clin Biochem; 1993 Jul; 31(7):427-32. PubMed ID: 8399782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres.
    Ma J; Samuel J; Kwon GS; Noujaim AA; Madiyalakan R
    Cancer Immunol Immunother; 1998 Sep; 47(1):13-20. PubMed ID: 9755874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic cascades after injection of the monoclonal antibody OC125. A study in a mouse model.
    Schultes BC; Reinsberg J; Wagner U; Schlebusch H; Richter H; Krebs D; Biersack HJ
    Cell Biophys; 1994; 24-25():259-66. PubMed ID: 7736531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
    Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
    J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
    Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
    Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Falsely low results in CA 125 determination due to anti-idiotypic antibodies induced by infusion of [131I]F(ab')2 fragments of the OC125 antibody.
    Reinsberg J; Nocke W
    Eur J Clin Chem Clin Biochem; 1993 May; 31(5):323-7. PubMed ID: 8357942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.
    Möbus VJ; Baum RP; Bolle M; Kreienberg R; Noujaim AA; Schultes BC; Nicodemus CF
    Am J Obstet Gynecol; 2003 Jul; 189(1):28-36. PubMed ID: 12861134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).
    Schultes BC; Baum RP; Niesen A; Noujaim AA; Madiyalakan R
    Cancer Immunol Immunother; 1998 Jun; 46(4):201-12. PubMed ID: 9671143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.
    Uttenreuther-Fischer MM; Feistel H; Wolf F; Jäger W
    J Clin Lab Anal; 1997; 11(2):94-103. PubMed ID: 9058243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring cancer antigen 125 in serum of ovarian cancer patients after administration of 131I-labeled F(ab')2 fragments of OC125 antibody.
    Reinsberg J; Schultes B; Wagner U; Krebs D
    Clin Chem; 1993 May; 39(5):891-6. PubMed ID: 8485883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A trial with immunotherapy of ovarian cancer by idiotype vaccination. Activation of the idiotype network in patients with advanced ovarian cancers by treatment with monoclonal antibody OC125].
    Wagner U; Reinsberg J; Krebs D
    Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):785-8. PubMed ID: 2286317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine.
    Nustad K; Bast RC; Brien TJ; Nilsson O; Seguin P; Suresh MR; Saga T; Nozawa S; Børmer OP; de Bruijn HW; Nap M; Vitali A; Gadnell M; Clark J; Shigemasa K; Karlsson B; Kreutz FT; Jette D; Sakahara H; Endo K; Paus E; Warren D; Hammarström S; Kenemans P; Hilgers J
    Tumour Biol; 1996; 17(4):196-219. PubMed ID: 8685601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection.
    Reinsberg J; Heydweiller A; Wagner U; Pfeil K; Oehr P; Krebs D
    Clin Chem; 1990 Jan; 36(1):164-7. PubMed ID: 2297919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose.
    Reinsberg J; Wagner U; Krebs D
    Arch Gynecol Obstet; 1994; 255(1):9-18. PubMed ID: 8042882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique.
    Schlebusch H; Reinartz S; Kaiser R; Grünn U; Wagner U
    Hybridoma; 1997 Feb; 16(1):47-52. PubMed ID: 9085128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
    Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
    Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of human monoclonal anti-idiotypic antibodies with specificity to the murine monoclonal anti-CA 125 antibody B43.13.
    Oltrogge JB; Donnerstag B; Baum RP; Noujaim AA; Träger L
    Int J Biol Markers; 1996; 11(4):211-5. PubMed ID: 9017445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.